Paul D'Angio
Director/Board Member at NEXIMMUNE, INC.
Net worth: 3 795 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sol Barer | M | 76 |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 38 years |
| Kristi Jones | F | 60 | 7 years | |
| Frank Bedu-Addo | M | 59 | 5 years | |
| Stephen Glover | M | 60 | 5 years | |
| Mathias Oelke | M | 56 | 13 years | |
| Alan Roemer | M | 54 | 7 years | |
| Tim Bertram | M | 68 | 7 years | |
| Gregory Freitag | M | 62 | 5 years | |
| Grant Verstandig | M | 34 | 3 years | |
| Kamil Ali-Jackson | F | 65 | 4 years | |
| Zheng Bin Yao | M | 58 | 7 years | |
| Richard Sykes | M | 79 | 5 years | |
| Matthew Schiller | M | - | 3 years | |
| Ilian Iliev | M | 48 | 4 years | |
| Chad Rubin | M | - | 3 years | |
| Leena Gandhi | M | 53 | 2 years | |
| Tonya Catterton | F | - | - | |
| Karen Haslbeck | F | - | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Alles | M | 64 | 15 years | |
| Jacqualyn Fouse | M | 62 | 7 years | |
| Scott Carmer | M | 59 | 8 years | |
| Robert Hugin | M | 69 | 19 years | |
| Andrew Saik | M | 54 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 3 years |
| Albert Marchio | M | 72 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 4 years |
| Kenneth Carter | M | 65 | 6 years | |
| Jonathan Biller | M | 61 | 8 years | |
| James J. Loughlin | M | 81 | 12 years | |
| Robert Spiegel | M | 73 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 6 years |
| Peter Kellogg | M | 67 | 5 years | |
| Timothy J. Smith | M | - | - | |
| Thomas Daniel | M | 69 | 10 years | |
| Robert Macdonald | M | 62 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 9 years |
| Perry Karsen | M | 69 | 9 years | |
| Scott Smith | M | 61 | 10 years | |
| Alain D. Cappeluti | M | - | - | |
| Sandy Mahatme | M | 59 | 6 years | |
| Gerald F. Masoudi | M | 56 | 3 years | |
| Rosemary Crane | F | 64 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 2 years |
| Liam Ratcliffe | M | 60 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 3 years |
| Carrie Cox | F | 66 | 10 years | |
| Julia Haller | M | 69 | - | |
| Rupert Vessey | M | 59 | 4 years | |
| Robert Knight | M | 73 | 16 years | |
| Jay Backstrom | M | 69 | 11 years | |
| Thomas Perone | M | 59 | 12 years | |
| Jerome Zeldis | M | 74 | 22 years | |
| Tim Stover | M | - | 3 years | |
| Kurt Conti | M | 61 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 8 years |
| Richard W. Barker | M | 75 | 7 years | |
| Robert Hershberg | M | 61 | 5 years | |
| Lawrence V. Stein | M | 74 | 3 years | |
| Rodman L. Drake | M | 80 | 8 years | |
| John W. Jackson | M | 78 | 10 years | |
| Richard Morgan | M | 79 | 29 years | |
| William Rastetter | M | 76 | 6 years | |
| Ernest Mario | M | 85 | 12 years | |
| Michael Friedman | M | 80 | 8 years | |
| James Healy | M | 59 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 3 years |
| Michael D. Casey | M | 78 | 17 years | |
| Brendan Delaney | M | 49 | 6 years | |
| Patrick E. Flanigan | M | - | - | |
| Michael Bonney | M | 65 | 4 years | |
| Tony Yao | M | 51 | - | |
| W. Middlekauff | M | 63 | - | |
| Nadim Ahmed | M | 56 | 9 years | |
| Stanley Frankel | M | 65 | 4 years | |
| Kevin Patrick Lynch | M | 59 | 8 years | |
| Terrence Connolly | M | - | 8 years | |
| Alexander Reynolds | M | - | 13 years | |
| Xiao Ping Dai | M | - | 4 years | |
| Gregory Russotti | M | 57 | 13 years | |
| Katherine Stultz | F | 51 | 15 years | |
| Deanna Weber | F | - | - | |
| Robert Schmidt | M | 47 | 3 years | |
| Emily Minkow | F | 41 | 7 years | |
| Benjamin Winograd | M | 63 | 13 years | |
| Jennifer Creel | F | 53 | 12 years | |
| Johan Lund | M | 67 | 1 years | |
| John F. Chin | M | 58 | 15 years | |
| Adrienne Farid | M | 62 | 3 years | |
| Frank T. Cary | M | 103 | 19 years | |
| Shubh Goel | M | 51 | 4 years | |
| Hunter Smith | M | 56 | 4 years | |
| Kristen Hege | M | 60 | 9 years | |
| Alan Colowick | M | 61 | 7 years | |
| Arthur Hull Hayes | M | 89 | 15 years | |
| Walter L. Robb | M | 95 | 19 years | |
| Dennis Cho | M | 53 | 9 years | |
| Jillian F. Evans | M | - | 1 years | |
| Catherine B. Elflein | F | 63 | 14 years | |
| Robert Tessarolo | M | 56 | 2 years | |
| Jian Ming Mei | M | 58 | 9 years | |
| Edward Dulac | M | 49 | 8 years | |
| Neil Desai | M | 59 | 6 years | |
| Maureen T. Cronin | M | 70 | 5 years | |
| Justin Chakma | M | 35 | 3 years | |
| Randall M. Stevens | M | - | - | |
| Terrie Curran | F | 55 | 6 years | |
| Michael Pehl | M | 60 | 11 years | |
| George Golumbeski | M | 67 | 9 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul D'Angio
- Personal Network
